Literature DB >> 6502473

Lack of influence of an intensive antacid regimen on theophylline bioavailability.

R C Reed, H J Schwartz.   

Abstract

We examined the influence of a large-volume, therapeutic antacid regimen, administered for three full days, on the steady-state bioavailability of a conventional-release and sustained-release theophylline product, Aminophyllin and Theodur, respectively. Nine stable asthmatics voluntarily completed a four-phase investigation requiring a total stay of 12 days in the Clinical Research Unit. The treatments consisted of administration of the formulations mentioned with and without antacids to each patient in a randomized sequence. Four patients participated in an additional phase where antacids were administered q2h around the clock for three days. After coadministration of theophylline plus antacids for two days, theophylline therapy was discontinued while numerous blood samples were obtained over 22 hr and analyzed for theophylline content via radioimmunoassay. Antacids had no predictable, consistent influence on theophylline absorption rate as determined by the absorption rate constant, the time to maximal theophylline concentration, or the lag time for theophylline absorption. Antacids had no detectable influence on theophylline elimination half-life and had no consistent, statistically significant effect on the extent of theophylline bioavailability, according to measurements of maximal concentration, AUC measured over the appropriate steady-state dosing interval, or elimination-rate adjusted AUC. The substantial intraindividual changes for all parameters of theophylline bioavailability that occurred for control and treatment phases likely represent spontaneous, random between-day variability in theophylline disposition independent of antacid administration, as evidenced by the comparability of the percent coefficient of variation for parameters of bioavailability across all phases. Our data demonstrate that therapeutic antacid administration has no effect on steady-state theophylline bioavailability and does not alter the intrinsic variability in theophylline absorption. Based on the results of our data, it is unlikely that a clinically significant (greater than 20%) decrease in theophylline absorption would occur in any patient treated intensively with antacids concurrently.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502473     DOI: 10.1007/bf01061723

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  34 in total

1.  Acute peptic ulceration in emphysema.

Authors:  F J FLINT; A J WARRACK
Journal:  Lancet       Date:  1958-07-26       Impact factor: 79.321

2.  Theophylline toxicity in an infant.

Authors:  B Badiei; R M Sly
Journal:  Ann Allergy       Date:  1975-11

3.  Stimulation of gastric secretion in man by theophylline ethylenediamine.

Authors:  S KRASNOW; M I GROSSMAN
Journal:  Proc Soc Exp Biol Med       Date:  1949-07

4.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

6.  Intraindividual variability in theophylline pharmacokinetics: statistical verification in 39 of 60 healthy young adults.

Authors:  R A Upton; J F Thiercelin; T W Guentert; S M Wallace; J R Powell; L Sansom; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

7.  Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products.

Authors:  L Shargel; J A Stevens; J E Fuchs; A B Yu
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

8.  Modification of the theophylline radioimmunoassay.

Authors:  R C Reed; E S Burkett; C M Myers; H J Schwartz; R Salazar
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

9.  Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial.

Authors:  A F Ippoliti; R A Sturdevant; J I Isenberg; M Binder; R Camacho; R Cano; C Cooney; M M Kline; R L Koretz; J H Meyer; I M Samloff; A D Schwabe; E A Strom; J E Valenzuela; R H Wintroub
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

10.  Intrasubject variation in sustained-release theophylline absorption.

Authors:  R A Dederich; S J Szefler; E R Green
Journal:  J Allergy Clin Immunol       Date:  1981-06       Impact factor: 10.793

View more
  6 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 3.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

4.  Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation.

Authors:  J F Muir; G Peiffer; M O Richard; D Benhamou; M Andrejak; L Hary; N Moore
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing.

Authors:  A Lindholm; S Henricsson; M Lind; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Effects of antacids on the clinical pharmacokinetics of drugs. An update.

Authors:  R Gugler; H Allgayer
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.